Clinical Trial Update: Safety and Dialysability of Dotarem® in Dialysed Patients [Phase 1]

View source ↗

Summary

This Phase 1 study assessed the safety and dialysability of the MRI contrast agent Dotarem (gadoterate meglumine) in patients with end-stage renal disease under…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• DOTAREM (Gadoterate meglumine)

Snippet

Sponsor: Guerbet | Conditions: End-stage Renal Failure | Phase 1 | Status: COMPLETED | Results posted: 2015-06-08